Search Results
1 - Taro Files Lawsuit against Sun in U.S. Federal Court
HAWTHORNE, N.Y.-(Business Wire)-September 29, 2009 - Taro Pharmaceutical Industries Ltd. (“Taro,” the “Company,” Pink Sheets: TAROF) filed a lawsuit today against Sun Pharmaceutical Industries Ltd. and certain of its affiliates (collectively, “Sun”) in the United States District Court...
2 - Vitae Receives $8 Million Payment from Boehringer Ingelheim for Achievement of 11beta-HSD-1 Program Milestone
FORT WASHINGTON, Pa.-(Business Wire)-September 29, 2009 - Vitae Pharmaceuticals, Inc., an integrated discovery and development company, today announced that it has earned an $8 million milestone payment from Boehringer Ingelheim for achievement of a performance milestone in their...
3 - Plexxikon Announces First Patient Dosed in First of Two Pivotal Trials of PLX4032 for Metastatic Melanoma
BERKELEY, Calif.-(Business Wire)-September 29, 2009 - Plexxikon Inc. announces that enrollment has been initiated and the first patient has been treated in the first of two pivotal trials of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly selective drug...
4 - Research and Markets: This Essential Report on India's Pharmacy Retail Market is Now Available
DUBLIN-(Business Wire)-September 29, 2009 - Research and Markets has announced the addition of the "Pharmacy Retail Market - India" report to their offering. The pharmacy retail market is valued at INR 216 bn in 2009 and estimated to reach INR 432 bn in 2011. The market is fragmented and dominated...
5 - Research and Markets: Slovenia Pharmaceuticals and Healthcare Report Q4 2009 - Now Available
DUBLIN-(Business Wire)-September 29, 2009 - Research and Markets For more information visit http://www.researchandmarkets.com/research/ff3d70/slovenia_pharmaceu
6 - Acrux Announces Successful AXIRON™ Phase III Trial Results
NEW YORK-(Business Wire)-September 29, 2009 - Australian company, Acrux, today announced positive results from a Phase III trial evaluating the safety and efficacy of AXIRON™ in 155 men with testosterone deficiency (hypogonadism), across 26 sites in six countries. AXIRON™ is applied to the...
7 - Research and Markets: Turkey Pharmaceuticals and Healthcare Report Q4 2009
DUBLIN-(Business Wire)-September 29, 2009 - Research and Markets Biomeks For more information visit http://www.researchandmarkets.com/research/0423af/turkey_pharmaceuti
8 - Burzynski Research Institute Signs Research Agreement with the University of Alabama at Birmingham (UAB), Division of Preventive Medicine, Biostatistics and Bioinformatics Shared Facility
HOUSTON-(Business Wire)-September 28, 2009 - The Burzynski Research Institute, Inc. (BRI) today announced that it has signed a Research Agreement with the UAB Division of Preventive Medicine, Biostatistics and Bioinformatics Shared Facility (BBSF) that will provide biostatistical and data management...
9 - Wedgewood Pharmacy CEO Receives Highest Annual Alumni Award from Philadelphia College of Pharmacy
SWEDESBORO, N.J.-(Business Wire)-September 28, 2009 - George J. Malmberg, R.Ph., F.A.C.A., F.A.C.V.P., the pharmacist president and chief executive officer of Wedgewood Pharmacy (Swedesboro, NJ) was the 55th recipient of the Annual Alumni Award from the Philadelphia College of Pharmacy (PCP) of...
10 - Ligand and GlaxoSmithKline Collaboration Identifies New Compound
SAN DIEGO-(Business Wire)-September 28, 2009 - Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that pursuant to an amendment to a March 2006 research agreement with GlaxoSmithKline (NYSE:GSK), GSK has agreed to accelerate the timing of a $500,000 payment to Ligand that would...
11 - Merck & Co., Inc. Obtains Exclusive U.S. Marketing Rights for AFLURIA®, Seasonal Influenza Vaccine from CSL Biotherapies
WHITEHOUSE STATION, N.J.-(Business Wire)-September 28, 2009 - Merck & Co., Inc. announced today that the Company has entered into an exclusive agreement with CSL Biotherapies, a subsidiary of CSL Limited, to market and distribute AFLURIA® (Influenza Virus Vaccine), CSL's seasonal influenza...
12 - Teva Provides Update on Generic Seroquel® Litigation
JERUSALEM-(Business Wire)-September 25, 2009 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Court of Appeals for the Federal Circuit has affirmed a July 1, 2008 decision by the District Court to grant AstraZeneca’s motion for summary judgment of no inequitable...
13 - NCPA Applauds Senate Committee’s Vote to Reduce Health Care Costs by Approving Transparency Requirements for Pharmacy Benefit Managers
ALEXANDRIA, Va.-(Business Wire)-September 25, 2009 - The National Community Pharmacists Association (NCPA) today commended the U.S. Senate Finance Committee for approving by unanimous, voice vote an amendment by U.S. Sen. Maria Cantwell (D-WA) to lower health care costs through common-sense...
14 - PCMA: Senate Finance Committee ‘Disclosure’ Amendment Will Increase Prescription Drug Costs
WASHINGTON-(Business Wire)-September 25, 2009 - Mark Merritt, President of the Pharmaceutical Care Management Association (PCMA) issued the following statement after the Senate Finance Committee’s adoption of a PBM disclosure amendment sponsored by Senator Maria Cantwell (D-Wash...
15 - Quintiles and Allergan Announce Co-Promotion for Sanctura XR®
RESEARCH TRIANGLE PARK, N.C.-(Business Wire)-September 25, 2009 - Quintiles Transnational Corp. and Allergan, Inc. (NYSE: AGN) today announced an agreement under which Quintiles will co-promote Allergan's SANCTURA XR® (trospium chloride extended release capsules), an anticholinergic approved for...
16 - Frances D. Fergusson And John P. Mascotte Elected To Pfizer’s Board Of Directors
NEW YORK-(Business Wire)-September 25, 2009 - Pfizer Inc today announced the election of Frances D. Fergusson, Ph.D. and John P. Mascotte to its Board of Directors. Dr. Fergusson and Mr. Mascotte, current members of the Board of Directors of Wyeth, will join the Pfizer Board upon the closing of...
17 - Altor BioScience Awarded $3 MM SBIR Bridge Grant by NCI to Advance Clinical Trials for its Targeted Cancer Therapeutic ALT-801
MIRAMAR, Fla.-(Business Wire)-September 25, 2009 - Altor BioScience Corporation announced today that it has been awarded a Small Business Innovation Research (SBIR) Phase II Bridge Grant by the National Cancer Institute (NCI). The award of $3 MM over three years will help Altor further its...
18 - Allos Therapeutics’ FOLOTYN™ First and Only FDA-Approved Therapy for Relapsed or Refractory Peripheral T-cell Lymphoma
WESTMINSTER, Colo.-(Business Wire)-September 25, 2009 - Allos Therapeutics, Inc. (Nasdaq:ALTH) today announced that last night the U.S. Food and Drug Administration (FDA) granted accelerated approval for FOLOTYNTM (pralatrexate injection) for use as a single agent for the treatment of patients...
19 - Advaxis Cures Late Form 10-Q Filing
NORTH BRUNSWICK, N.J.-(Business Wire)-September 24, 2009 - Advaxis, Inc. (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) vaccine company, announced today that the Company's ticker symbol has been temporarily changed to ADXSE denoting untimely filing of the Company’s July 31, 2009...
20 - Reportlinker Adds RFID in Healthcare and Pharmaceuticals 2009-2019
NEW YORK-(Business Wire)-September 24, 2009 - Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds RFID in Healthcare and Pharmaceuticals 2009-2019...
